$ORGO News

Truist Securities Initiates Coverage On Organogenesis Holdings with Hold Rating, Announces Price Target of $3

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

Spotlight On Penny Stocks To Consider In May 2026

Undervalued Small Caps With Insider Buying To Watch In May 2026

Organogenesis (ORGO) Q1 2026 Earnings Transcript

Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary

Organogenesis Q1 Earnings Call Highlights

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

Organogenesis Holdings Lowers FY2026 Sales Guidance from $350.000M-$420.000M to $270.000M-$310.000M vs $401.200M Est

Organogenesis Hldgs Q1 Adj. EPS $(0.34) Misses $(0.31) Estimate, Sales $36.250M Miss $43.300M Estimate

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

Organogenesis Completes Rolling BLA Submission To FDA For ReNu, Cryopreserved, Amniotic Suspension Allograft Developed For Management Of Symptomatic Knee Osteoarthritis

Organogenesis Completes Rolling BLA Submission To FDA For ReNu, Cryopreserved, Amniotic Suspension Allograft Developed For Management Of Symptomatic Knee Osteoarthritis

What's Going On With Organogenesis Stock On Wednesday?

Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight

Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win

Organogenesis shares are trading higher after the company announced that its trial evaluating PuraPlyAM plus standard of care achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks.

Reported Earlier, Organogenesis Reports PuraPly AM Meets Primary Endpoint In Randomized Controlled Trial, Demonstrating Statistically Significant DFU Wound Closure At 12 Weeks

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM